SOD1 and acute myeloid leukemia: Specifically, AML cell lines (U937, HL-60, and THP-1) and AML patient cells treated with 5.0 μM AZA for 24 h exhibited reduced intracellular ROS levels, alongside an increase in total antioxidant capacity, including enhanced SOD and GSH activity (Table 1) [6].